OC
LIVE

Serial Number

79213106

Owner

ANEMOCYTE S.R.L.

Attorney

Brian A. Tollefson

Filing Date

Feb 6, 2017

Add to watchlist:

No watchlists yet
View on USPTO

OC Trademark

Serial Number: 79213106 • Registration: 5466730

OC is a trademark filed by ANEMOCYTE S.R.L. on February 6, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ANEMOCYTE S.R.L. (5 trademarks)

Via R. Lepetit, 34

Entity Type: 16

Trademark Details

Filing Date

February 6, 2017

Registration Date

May 15, 2018

Published for Opposition

February 27, 2018

Goods & Services

Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; Research and development in the pharmaceutical and biotechnology fields; Research and development in the field of micro-organisms and cells; Research and development in the field of biochemistry; Scientific research and development in the field of biology; Research and development in the field of diagnostic preparations; Services of medical laboratories; Compiling medical information and data for research and development purposes in the medical and veterinary fields; Scientific and technological services, namely, scientific research and technical writing; Scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes in the field of biology

Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all ] for use in human [ and veterinary ] medicine; Chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Prescription and non-prescription ] medicines, [ namely, pills, tablets, capsules, caplets, liquid drops, sachets, and ] pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; ] Biological preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; ] Biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Diagnostic preparations for medical purposes; ] Medicines for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; ] Biological reagents for medical use; Medicinal preparations based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; [ Medicinal preparations based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; Products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, natural killer cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ Gene therapy products, namely, genetically engineered tissues for transplant purposes; Medicaments, namely, cells and tissues that have been subjected to extensive manipulation, to help assist with the regeneration of ligament and tendon fibers; ] Preparations for personalized medicine made of [ autologous cells or proteins or ] nucleic acids derived from individual genomic sequences; [ Preparations made up of cells for medical or clinical use; ] Preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; Preparations made up of tissues, namely, biological tissue cultures for medical purposes; Vaccines; Recombinant proteins supplements; Therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Feb 6, 2026 INPS
INVALIDATION PROCESSED
Feb 6, 2026 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 18, 2025 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jun 13, 2025 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jun 13, 2025 C75A
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Jun 5, 2025 EROP
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
Dec 18, 2024 PR75
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 16, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
May 14, 2024 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 15, 2023 REM3
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 24, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 24, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 24, 2022 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 24, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 24, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 24, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 24, 2022 COAR
NEW REPRESENTATIVE AT IB RECEIVED
Apr 9, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 15, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 24, 2018 FICS
FINAL DISPOSITION PROCESSED
Aug 24, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 15, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
May 15, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 27, 2018 NPUB
PUBLISHED FOR OPPOSITION
Feb 27, 2018 PUBO
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 22, 2018 ADCH
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 7, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 25, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 25, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 25, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 25, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 25, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 22, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 22, 2018 CRFA
ASSIGNED TO LIE
Jan 18, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 3, 2018 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 20, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 20, 2017 REAP
REFUSAL PROCESSED BY IB
Aug 18, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 3, 2017 RFCS
REFUSAL PROCESSED BY MPU
Aug 3, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 1, 2017 RFCR
APPLICATION FILING RECEIPT MAILED
Aug 1, 2017 MAFR
NON-FINAL ACTION WRITTEN
Jul 31, 2017 CNRT
ASSIGNED TO EXAMINER
Jul 28, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 28, 2017 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 27, 2017 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 27, 2017 REPR